Streetbeat News

Products Services

ALLR

Allarity Therapeutics announced that multiple patients in its Phase 2 Stenoparib trial have exceeded 30 weeks on treatment, indicating positive progress in the trial.

Portfolio Pulse from Benzinga Newsdesk

June 25, 2024 | 12:10 pm

LFMD

LifeMD, Inc. (NASDAQ:LFMD) has launched private health insurance acceptance for its virtual primary care services, including weight management. Initially available in select states, the company plans to expand coverage nationwide and begin accepting Medicare by early 2025.

Portfolio Pulse from Benzinga Newsdesk

June 25, 2024 | 12:10 pm

NNOX

NANO-X IMAGING announced that data for its Nanox.AI technology will be presented at the Society of Cardiovascular Computed Tomography (SCCT) conference.

Portfolio Pulse from Benzinga Newsdesk

June 25, 2024 | 12:10 pm

ALLR

Allarity Therapeutics (NASDAQ: ALLR) announced that multiple patients in its Phase 2 clinical trial of stenoparib for advanced recurrent ovarian cancer have been on treatment for more than 30 weeks, indicating extended clinical benefit.

Portfolio Pulse from Benzinga Newsdesk

June 25, 2024 | 12:09 pm

BTBT

DELL

NVDA

Bit Digital has finalized an agreement to supply an existing customer with an additional 2,048 GPUs over a three-year term, totaling 4,096 GPUs and generating approximately $275 million in revenue. The company has placed a purchase order for 256 servers from Dell Technologies, equipped with Nvidia HGX H100 GPUs, to be delivered in July 2024. Bit Digital is also evaluating debt financing options for its hardware assets.

Portfolio Pulse from Benzinga Newsdesk

June 25, 2024 | 12:09 pm

EKSO

Ekso Bionics has announced a research partnership with Shepherd Center to expand the use of its EksoNR and Ekso Indego devices in rehabilitation and community settings. The partnership aims to improve the quality of life for patients with spinal cord and brain injuries, multi-trauma, amputations, stroke, multiple sclerosis, and pain.

Portfolio Pulse from Benzinga Newsdesk

June 25, 2024 | 12:09 pm

DJT

Trump Media & Technology Group Corp (NASDAQ:DJT) saw a significant surge of over 21% on Monday, recovering from a decline following Trump's legal issues. The stock closed at $33.52, up from $27 on Friday. The company expects to generate over $69.4 million from exercised warrants, but concerns about stock dilution remain. Short sellers have faced substantial losses, totaling $178 million year-to-date. Trump is also set to speak at the Bitcoin 2024 convention, highlighting his pro-crypto stance.

Portfolio Pulse from Anusuya Lahiri

June 25, 2024 | 12:08 pm

HRMY

The FDA has confirmed a favorable benefit-risk profile for WAKIX, a drug by Harmony Biosciences. The company plans to launch at least one new product or indication annually over the next five years. The denial of a citizen petition further confirms WAKIX's safety and efficacy for treating EDS and cataplexy in adults with narcolepsy.

Portfolio Pulse from Benzinga Newsdesk

June 25, 2024 | 12:07 pm

RIVN

Rivian Automotive, Inc. (NASDAQ:RIVN) shares are rising in premarket trading following a positive analyst action from Guggenheim Securities, which initiated coverage with a Buy rating and an $18 price target. The optimism is based on a compelling catalyst path for Rivian's R2/R3 vehicles. Despite industry-wide demand slowdowns and significant losses per EV, Rivian's new, more affordable R2 vehicles are expected to boost its prospects.

Portfolio Pulse from Shanthi Rexaline

June 25, 2024 | 12:06 pm

LPCN

Lipocine announced that its drug LPCN 1154 met the standard bioequivalence criteria and was well tolerated with no sedation or somnolence events. The company is on track for an NDA filing, targeting Q4 2024.

Portfolio Pulse from Benzinga Newsdesk

June 25, 2024 | 12:06 pm